Filing Flows › Zentalis Pharmaceuticals (ZNTL) › Stock forecast & fair value
Zentalis Pharmaceuticals (ZNTL) stock forecast and price target
Zentalis Pharmaceuticals (ZNTL) trades at $1.72. 9 analysts' median price target is $7.00 (+307%), from $5.00 to $10.00.
Zentalis Pharmaceuticals' latest quarter
Zentalis Pharmaceuticals, Q4 2024: revenue $26.9M, operating margin -185.6%, net loss $47.5M, operating cash flow −$39.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for ZNTL stock?
The median of 9 analysts' 12-month targets is $7.00, +307% from $1.72; the range is $5.00 to $10.00. The average rating is buy.
Does Zentalis Pharmaceuticals usually beat earnings estimates?
It beat the consensus EPS estimate in 67% of the quarters on record.
Is ZNTL stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.